Create account

Coverage dated November 6, 2026

Moderna raised its full-year sales outlook after a bigger-than-expected profit

Headline from Quartz

The drugmaker's 2026 revenue growth forecast is 15% to 25%, up from up to 10%; its year-end cash outlook rose to $8.1 billion to $8.3 billion

Quartz's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

3 articles, oldest first.

  1. Bloomberg

    Moderna Boosts Revenue Guidance on Covid Vaccine Sales (opens Bloomberg)

    Published

    Bloomberg's feed description

    Moderna Inc. boosted its full-year guidance and posted its first quarterly profit since 2024 as Covid vaccine sales rebounded strongly from a year ago.

  2. Quartz

    Moderna raised its full-year sales outlook after a bigger-than-expected profit (opens Quartz)

    Published

    Quartz's feed description

    The drugmaker's 2026 revenue growth forecast is 15% to 25%, up from up to 10%; its year-end cash outlook rose to $8.1 billion to $8.3 billion

  3. Investor's Business Daily

    Moderna Hits Five-Year High On Sales Beat; But The Real Story Is Still Its Cancer Vaccine (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    Moderna stock surged to a five-year high Friday on the back of its Street-walloping vaccine sales and guidance hike for the year.